Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)
Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities
- Published
- 20 May 2026
- Closes
- 30 Sept 2026, 23:59 UTC
- Value
- USD 3,300,000
- Reference
- RFA-DK-27-147
- Location
- United States
- Sector
- Healthcare & Pharma
Details
This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks. Eligibility: Only the PI/PDs associated with the award issued under RFA-DK-20-509 to Beckman Research Institute/City of Hope is eligible to apply for this single source funding. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Estimated total programme funding: USD 3300000
Expected number of awards: 1
CFDA number(s): 93.847
Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.
Context for bidders
We hold 408 notices from National Institutes of Health, going back to May 2023 — 390 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 398 open Healthcare & Pharma tenders in United States. This one closes in 6 days.
More from this buyer
- Limited Competition: NIH Research Evaluation and Commercialization Hubs (REACH) (SB0 Clinical Trial Optional)· closes 10 Nov
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)· closes 10 Nov
- Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)· closes 25 May
- NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)· closes 17 Apr
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)· closes 10 Nov
Similar Healthcare & Pharma tenders
- Advancing bio-printing of living cells for regenerative medicine· closes 22 Sept
- Development of cell-free protein synthesis platforms for discovery and/or production of biologicals· closes 13 Apr
- Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential· closes 13 Apr
- Development of innovative antimicrobials against pathogens resistant to antimicrobials· closes 13 Apr
- Development of monoclonal antibodies to prevent and treat infections from Flaviviruses· closes 13 Apr
Before you bid on this tender
A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.
- Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
- Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
- Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
- Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
- Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
- Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.
More Healthcare & Pharma tenders
- Provision of Private Hospital Capacity to support Urgent and Emergency CareHealth Service Executive (HSE) · Ireland
- Panel for Counselling and Psychotherapy ServicesUniversity College Dublin ( UCD ) · Ireland
- HSE 28439 - Restricted Procedure to procure a HSE Enterprise Integration Platform as a Service ( EiPaaS)Health Service Executive (HSE) · Ireland
- Provision of Occupational Health ServicesUisce Éireann · Ireland
- Supply of Accessibility Ramps, Wheelchair lifts, Parts and Servicing, Maintenance and TrainingBus Eireann/Irish Bus · Ireland
FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.
Verify & apply on the official portal →